Estrogen therapy in Turner syndrome: Does the type, dose and mode of delivery matter?

Pediatric Endocrinology Reviews

Volumn 9, Issue SUPPL. 2, 2012, Pages 718-722

  Mauras, Nelly ^a   Torres Santiago, Lournaris ^a,c   Taboada, Martha ^a,b   Santen, Richard ^d  

^a NEMOURS CHILDREN S CLINIC   (United States)

^b University of Florida Health Sciences Campus ^*

^c UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

(8): Estradiol; Estrone; Hypogonadism; IGF I; Pharmacokinetics; Puberty; Transdermal; Turner syndrome

Indexed keywords

CONJUGATED ESTROGEN; DEPOGYNOGEN; ESTRADIOL; ESTRADIOL CIPIONATE; ESTROGEN; ESTROGEN PLUS PROGESTIN; ETHINYLESTRADIOL; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

BIOEQUIVALENCE; BODY FAT DISTRIBUTION; BONE DENSITY; CHILD GROWTH; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DRUG CHOICE; DRUG EFFECT; DRUG SCREENING; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; GROWTH HORMONE RELEASE; HUMAN; LIQUID CHROMATOGRAPHY; LUTEINIZING HORMONE BLOOD LEVEL; MASS FRAGMENTOGRAPHY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TANDEM MASS SPECTROMETRY; TURNER SYNDROME; UTERUS GROWTH; VAGINA CYTOLOGY;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; CHILD; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; HYPOGONADISM; TRANSDERMAL PATCH; TURNER SYNDROME;

EID: 84864554732     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med 2002;346:340-352
2. Drobac S, Rubin K, Rogol AD, Rosenfield RL. A workshop on pubertal hormone replacement options in the United States. J Pediatr Endocrinol Metab 2006;19:55-64 (Pubitemid 43257421)
3. Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991;72:374-381 (Pubitemid 21921702)
4. Cook DM, Ludlam WH, Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab 1999;84:3956-3960 (Pubitemid 30644180)
5. O'Sullivan AJ, Crampton LJ, Freund J, Ho KK. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest 1998;102:1035-1040 (Pubitemid 28419248)
6. Hanggi W, Lippuner K, Jaeger P, Birkhauser MH, Horber FF. Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women. Clin Endocrinol 1998;48:691-699 (Pubitemid 28289236)
7. Gravholt CH, Hjerrild BE, Naeraa RW, Engbaek F, Mosekilde L, Christiansen JS. Effect of growth hormone and 17b-oestradiol treatment on metabolism and body composition in girls with Turner syndrome. Clin Endocrinol 2005;62:616-622 (Pubitemid 40646732)
8. Nabhan ZM, Dimeglio LA, Qi R, Perkins SM, Eugster EA. Conjugated oral versus transdermal estrogen replacement in girls with Turner syndrome: a pilot comparative study. J Clin Endocrinol Metab 2009;94:2009-2014
9. Mauras N, Shulman D, Hsiang HY, Balagopal P, Welch S. Metabolic effects of oral versus transdermal estrogen in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab 2007;92:4154-4160 (Pubitemid 350074725)
10. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL. Biologic effects of transdermal estradiol. N Engl J Med 1986;314:1615-1620 (Pubitemid 16118219)
11. Santen RJ, Demers L, Ohorodnik S, Settlage J, Langecker P, Blanchett D, Goss PE, Wang S. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 2007;72:666-671 (Pubitemid 46977432)
12. Santen RJ, Lee JS, Wang S, Demers LM, Mauras N, Wang H, Singh R. Potential role of ultra-sensitive estradiol assays in estimating the risk of breast cancer and fractures. Steroids 2008;73:1318-1321
13. Taboada M, Santen R, Lima J, Hossain J, Singh R, Klein KO, Mauras N. Pharmacokinetics and pharmacodynamics of oral and transdermal 176 estradiol in girls with Turner syndrome. J Clin Endocrinol Metab 2011;96:3502-3510
14. Nelson RE, Grebe SK, OKane DJ, Singh PJ. Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma. Clin Chem 2004;50:373-384 (Pubitemid 38156379)
15. Klein KO, Baron J, Colli MJ, McDonnell DP, Cutler GB Jr. Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest 1994; 94:2475-2480 (Pubitemid 24379624)